Menu

Doctor Who Blocked Thalidomide Dies

Frances Oldham Kelsey, a physician who halted use of a drug that caused birth defects in babies, has passed away at age 101.

Aug 11, 2015
Kerry Grens

WIKIMEDIA, THE US FOOD AND DRUG ADMINISTRATIONA physician and former medical reviewer for the US Food and Drug Administration (FDA), Frances Oldham Kelsey died last week (August 7). She was 101.

Kelsey is highly regarded for her work in denying approval for the medication thalidomide, which caused birth defects in babies when taken by pregnant women.

“Her exceptional judgment in evaluating a new drug for safety for human use has prevented a major tragedy of birth deformities in the United States,” President John F. Kennedy said of Kelsey, The New York Times reported.

Kelsey was a new medical officer at the FDA in 1960 when the application for thalidomide approval came across her desk. The medication was already used in Europe to treat nausea in pregnant women, but Kelsey was not convinced the treatment was safe. Her hesitation paid off, and evidence of the drug’s hazards began accumulating in the early 1960s.

The tragedy of thalidomide—and Kelsey’s demand for safety data—inspired new laws around the approval of new drugs and the evidence required to support their safety and efficacy.

Kelsey spent 45 years at the FDA, including leading the Office of Scientific Investigations. She “helped rewrite the nation’s medical-testing regulations, strengthening protections for people and against medical conflicts of interest,” the New York Times noted. “The rules have been adopted worldwide.”

“She had a huge effect on the regulations adopted in the 1960s to help create the modern clinical trial system,” Harvard University’s Daniel Carpenter, who wrote a book about the history of the FDA, told The Washington Post. “She may have had a bigger effect after thalidomide than before.”

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.